Abstract
A change in the lipoprotein profile is a metabolic hallmark of aging and has been the target for modern medical developments. Although pharmaceutical interventions aimed at lipid lowering substantially decrease the risk of cardiovascular disease, they have much less impact on mortality and longevity. Moreover, they have not affected death from other age-related diseases. In this review we focus on high density lipoprotein (HDL) cholesterol, the levels of which are either elevated or do not decrease as would be expected with aging in centenarians, and which are associated with lower prevalence of numerous age-related diseases; thereby, suggesting a potential HDL-mediated mechanism for extended survival. We also provide an update on the progress of identifying longevity-mediating lipid genes, describe approaches to discover longevity genes, and discuss possible limitations. Implicating lipid genes in exceptional longevity may lead to drug therapies that prevent several age-related diseases, with such efforts already on the way.
Current Vascular Pharmacology
Title:Phenotypes and Genotypes of High Density Lipoprotein Cholesterol in Exceptional Longevity
Volume: 12 Issue: 5
Author(s): Sofiya Milman, Gil Atzmon, Jill Crandall and Nir Barzilai
Affiliation:
Keywords: Aging, APOC3, CETP, genetics, HDL, longevity.
Abstract: A change in the lipoprotein profile is a metabolic hallmark of aging and has been the target for modern medical developments. Although pharmaceutical interventions aimed at lipid lowering substantially decrease the risk of cardiovascular disease, they have much less impact on mortality and longevity. Moreover, they have not affected death from other age-related diseases. In this review we focus on high density lipoprotein (HDL) cholesterol, the levels of which are either elevated or do not decrease as would be expected with aging in centenarians, and which are associated with lower prevalence of numerous age-related diseases; thereby, suggesting a potential HDL-mediated mechanism for extended survival. We also provide an update on the progress of identifying longevity-mediating lipid genes, describe approaches to discover longevity genes, and discuss possible limitations. Implicating lipid genes in exceptional longevity may lead to drug therapies that prevent several age-related diseases, with such efforts already on the way.
Export Options
About this article
Cite this article as:
Milman Sofiya, Atzmon Gil, Crandall Jill and Barzilai Nir, Phenotypes and Genotypes of High Density Lipoprotein Cholesterol in Exceptional Longevity, Current Vascular Pharmacology 2014; 12 (5) . https://dx.doi.org/10.2174/1570161111666131219101551
DOI https://dx.doi.org/10.2174/1570161111666131219101551 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inhibitors of Nitrogen Oxide Species Production in Animal Models of Inflammation and Future Directions for Therapy in Inflammatory Disorders
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Cardiac Dys-Synchronization and Arrhythmia in Hyperhomocysteinemia
Current Neurovascular Research Calcium Sensitizers in Cardiac Surgery: Who, When, How and Why?
Current Vascular Pharmacology Syntheses and In-Vitro Evaluation of Novel Adamantane Based γ-Secretase Inhibitors
Current Medicinal Chemistry Causes of Hospitalization in Systemic Lupus Erythematosus: A Narrative Review
Current Rheumatology Reviews Innate Immune Surveillance in the Central Nervous System Following Legionella pneumophila Infection
CNS & Neurological Disorders - Drug Targets Recent Developments of Melatonin Related Antioxidant Compounds
Combinatorial Chemistry & High Throughput Screening Therapeutic Utility and Medicinal Chemistry of Cathepsin C Inhibitors
Current Topics in Medicinal Chemistry Descriptive Analysis of Mortality Predictors in H1n1 Influenza in South Indian Patients
Infectious Disorders - Drug Targets The Prevention and Treatment of Delirium in Elderly Patients Following Hip Fracture Surgery
Recent Patents on CNS Drug Discovery (Discontinued) Basic Pharmacology of NMDA Receptors
Current Pharmaceutical Design Update on Glycoprotein IIb/IIIa: Role in Primary Coronary Intervention
Cardiovascular & Hematological Agents in Medicinal Chemistry Cerebral Collateral Circulation in Carotid Artery Disease
Current Cardiology Reviews Lipid Metabolism in Patients with End-Stage Renal Disease: A Five Year Follow-up Study
Current Vascular Pharmacology 12-Lipoxygenase: A Potential Target for Novel Anti-Platelet Therapeutics
Cardiovascular & Hematological Agents in Medicinal Chemistry Gestational Programming of Offspring Obesity: A Potential Contributor to Alzheimers Disease
Current Alzheimer Research Improvement of Apolipoprotein B in Argentine Indigenous School Children after Vitamin D Supplementation
Cardiovascular & Hematological Agents in Medicinal Chemistry Percutaneous Coronary Intervention in the Elderly: Are Drug-coated Balloons the Future?
Current Cardiology Reviews Current Therapeutic Strategies and Future Perspectives for the Treatment of Venous Thromboembolism
Current Pharmaceutical Design Absorption, Disposition and Pharmacokinetic Properties of Novel Therapeutic Modalities (Part II)
Current Drug Metabolism